Printed from

Cigna PBM expects big savings by adding Humira biosimilars to formulary

Posted On: Dec. 6, 2022 10:26 AM CST

Cigna Corp.’s pharmacy benefit manager Express Scripts on Dec. 5 said it will put multiple biosimilar versions of AbbVie Inc.’s expensive rheumatoid arthritis drug Humira in the “same position as the brand” on the PBM’s formulary in 2023, reports Forbes. Cigna’s decision means potentially thousands of patients could be shifted in 2023 to cheaper alternatives and save Cigna and Express Scripts clients and the U.S. healthcare system potentially billions of dollars a year.